Aptevo CFO converts 638 RSUs into common shares

Aptevo Therapeutics Inc. reported that SVP & CFO Daphne Taylor exercised 638 Restricted Stock Units on August 6, 2026.

Accepted by SEC EDGAR 08/10/2026 - 09:37 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Aptevo Therapeutics Inc. reported that SVP & CFO Daphne Taylor exercised 638 Restricted Stock Units on August 6, 2026. The RSUs converted into 638 shares of common stock on a one-for-one basis. These RSUs originated from an August 6, 2025 grant of 11,500 RSUs (638 post-split) that vested on the first anniversary of the grant date.

Insider Trade Summary

638 shares exercised/converted

Exercise 2 txns

Insider Taylor Daphne

Role SVP, CFO

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Unit F1, F2	638	$0.00	$0.00
Exercise	Common Stock F1	638	--	--

Holdings After Transaction: Restricted Stock Unit — 0 units (Direct); Common Stock — 638 shares (Direct)

Footnotes (2)

1. F1. Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis.
2. F2. On August 6, 2025, the reporting person was granted 11,500 (638 post-split) RSUs, vesting on the first anniversary of the date of grant.

Key Figures

RSUs exercised: 638 Restricted Stock Units Common shares acquired: 638 shares Original RSU grant: 11,500 RSUs (638 post-split) +2 more

5 metrics

RSUs exercised 638 Restricted Stock Units Converted into common stock on August 6, 2026

Common shares acquired 638 shares One-for-one conversion of vested RSUs

Original RSU grant 11,500 RSUs (638 post-split) Granted to Daphne Taylor on August 6, 2025

Per-share transaction price $0.0000 per share Reported for the RSU conversion transaction

Shares held after transaction 638 shares Direct ownership of common stock following RSU conversion

Key Terms

Restricted Stock Unit, derivative security, par value

3 terms

Restricted Stock Unit financial

"Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share"

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

derivative security financial

"transaction_code_description: Exercise or conversion of derivative security"

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

par value financial

"common stock, $0.001 par value per share, of the Issuer"

Par value is the fixed amount printed on a bond or stock that represents its original value when issued. It’s like the face value of a coin or bill—what the issuer promises to pay back or the starting price of a stock—though it often doesn’t change with market prices. It matters because it helps determine certain financial details, like how much the company will pay back at maturity.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Aptevo Therapeutics (APVO) report for Daphne Taylor?

Aptevo Therapeutics reported that SVP & CFO Daphne Taylor exercised 638 RSUs, which converted into 638 shares of common stock on August 6, 2026, following the vesting of a prior RSU grant.

How many Aptevo Therapeutics (APVO) shares were acquired through the RSU conversion?

Through the RSU conversion, Daphne Taylor acquired 638 shares of Aptevo common stock. These shares resulted from a one-for-one conversion of 638 vested Restricted Stock Units on August 6, 2026.

What was the origin of the 638 RSUs exercised at Aptevo Therapeutics (APVO)?

The 638 RSUs exercised by Daphne Taylor came from an August 6, 2025 grant of 11,500 RSUs (shown as 638 post-split), which were scheduled to vest on the first anniversary of the grant date.

Did the Aptevo Therapeutics (APVO) CFO pay a per-share price to exercise the RSUs?

The filing shows a $0.0000 per-share transaction price for the RSU exercise, indicating the 638 Restricted Stock Units converted into 638 common shares without an additional exercise price per share stated.

What type of securities were involved in the Aptevo Therapeutics (APVO) Form 4?

The Form 4 reports activity in Restricted Stock Units that are a derivative security and their conversion into common stock of Aptevo Therapeutics on a one-for-one basis.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Taylor Daphne

(Last) (First) (Middle)

2401 4TH AVENUE

SUITE 1050

(Street)

SEATTLE WASHINGTON 98121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Aptevo Therapeutics Inc. [ APVO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, CFO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/06/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/06/2026		M		638	A	(1)	638	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	(1)	08/06/2026		M			638	(2)	(2)	Common Stock	638	$0	0	D

Explanation of Responses:

1. Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis.

2. On August 6, 2025, the reporting person was granted 11,500 (638 post-split) RSUs, vesting on the first anniversary of the date of grant.

	/s/ SoYoung Kwon, Attorney-in-Fact	08/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)